Innominds & SCIINV Biosciences Launch AI-Powered Tool To Tackle Antimicrobial Resistance

Innominds, a digital transformation and product engineering company, has partnered with SCIINV Biosciences to introduce AMRx, an AI/ML-driven digital diagnostic tool aimed at addressing the growing threat of antimicrobial resistance (AMR). In a press statement on Thursday , the company said that this innovative solution aims to change the detection and treatment of antibiotic-resistant infections by eliminating the need for traditional culture methods.

The World Health Organization has identified AMR as one of the top ten global health threats. In 2019, AMR was responsible for an estimated 1.2 million deaths worldwide, and by 2050, it is projected that AMR-related fatalities could rise to 10 million annually, with a person dying from an antibiotic-resistant infection every 45 seconds. These statistics highlight the urgent need for effective solutions to combat AMR.

AMRx, developed by Innominds and SCIINV Biosciences, is a digital diagnostic tool that uses artificial intelligence and machine learning to predict urinary tract infections (UTIs) and determine antibiotic resistance patterns based on patient clinical history. This technology offers a culture-free approach to diagnosing infections, which can save valuable time and resources, particularly in settings with limited medical infrastructure.

The key features of AMRx include its ability to predict UTIs and identify causative organisms without the need for traditional cultures. This efficiency can streamline the diagnostic process and reduce unnecessary clinical investigations. Additionally, AMRx™ can support clinical decision-making by providing healthcare professionals with accurate data for empirical antibiotic prescriptions, potentially improving treatment outcomes.

Early diagnosis and treatment of infections are critical for improving patient outcomes and reducing the spread of antibiotic-resistant bacteria. The tool’s ability to provide timely and accurate diagnoses can play a significant role in achieving these goals. The adoption of such technology could also alleviate some of the burdens associated with manual record-keeping and traditional diagnostic methods, making healthcare delivery more efficient.

“Innominds is committed to leveraging technology to solve some of the world's most pressing healthcare challenges,” said Ravi Meduri, Executive Vice President, Digital and IP Solutions, Innominds. He emphasised that the partnership with SCIINV Biosciences and the development of AMRx are important steps in the mission to combat antimicrobial resistance and enhance patient care globally.

Prof. (Dr.) Ranga Reddy Burri, Advisor at SCIINV Biosciences Ltd and President of the Infection Control Academy of India, pointed out that traditional methods are falling short in the fight against the rapid spread of antimicrobial resistance. He stressed the importance of advanced digital technologies like AI and machine learning in developing new diagnostic tools and therapeutic solutions. According to Dr. Burri, innovative and scalable digital diagnostic tools are essential in addressing not only AMR but also other significant health challenges.